Ac-DEVD-CHO

Catalog No.S7901 Batch:S790101

Print

Technical Data

Formula

C20H30N4O11
Molecular Weight 502.47 CAS No. 169332-60-9
Solubility (25°C)* In vitro Water 100 mg/mL (199.01 mM)
 
 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ac-DEVD-CHO (Caspase-3 Inhibitor I, N-Ac-Asp-Glu-Val-Asp-CHO) is a potent aldehyde inhibitor of Group II caspases with Ki values of 0.2 nM and 0.3 nM for for caspase-3 and caspase-7, respectively. Weak inhibition for caspase-2.
Targets
Caspase-3 [1]
(Cell-free assay)		 caspase-8 [1]
(Cell-free assay)		 caspase-7 [1]
(Cell-free assay)		 caspase-10 [1]
(Cell-free assay)		 Caspase-1 [1]
(Cell-free assay)		 View More
230 pM(Ki) 0.92 nM(Ki) 1.6 nM(Ki) 12 nM(Ki) 18 nM(Ki)
In vitro Ac-DEVD-CHO is a potent inhibitor of caspase-3 (Ki = 230 pM). In contrast, caspase-2 cleaves the tetrapeptide substrate poorly and is only weakly inhibited by this aldehyde (Ki = 1.7 μM). Group III caspases are broadly inhibited by Ac-DEVD-CHO with Ki values ranging from 1 to 300 nM[1]. Inhibition of caspase-3 by Ac-DEVD-CHO in isolated working-heart rat model significantly improves post-ischemic contractile recovery of stunned myocardium, even when given after the onset of ischemia. The mechanism(s) of protection by Ac-DEVD-CHO appear to be independent of apoptosis. Troponin I cleavage was not inhibited by Ac-DEVD-CHO[2].
In vivo Ac-DEVD-CHO administered at the time of MI results in a 61% reduction in activated caspase-3 expression in cardiomyocytes (p<0.05), and an 84% reduction in cardiomyocyte apoptosis in the young animals. However, in the aging mice, caspase inhibition had no effect on activated caspase-3 expression or cardiomyocyte apoptosis[4]. Ac-DEVD-CHO suppressed and/or delayed the progression of photoreceptor cell damage in rats and delays disease progression in rd gene-carring mice, which normally develop retinal degeneration early in life[2].

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    MEFs

  • Concentrations

    20, 50 μM

  • Incubation Time

    2 h

  • Method

    Apaf-1−/− cells were treated with the indicated concentration of Ac-DEVD-CHO for 2 h prior to treatment with 4 μM CHX alone or with TNF for 6 h. LEHDase and DEVDase activities were standardized to the lactate dehydrogenase activity in the sample and are presented as percentages of the activity in TNF-plus-CHX-treated cells not treated with Ac-DEVD-CHO (0 μM).
Animal Study:

[4]
  • Animal Models

    C57Bl6 mice

  • Dosages

    3 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , Int J Oncol, 2018, 53(2):539-550]

Selleck's Ac-DEVD-CHO has been cited by 32 publications

AHR/cyp1b1 signaling-mediated extrinsic apoptosis contributes to 6PPDQ-induced cardiac dysfunction in zebrafish embryos [ Environ Pollut, 2024, 345:123467] PubMed: 38311157
The Interaction of HMGB1 with the Proinflammatory TREM-1 Receptor Generates Cytotoxic Lymphocytes Active against HLA-Negative Tumor Cells [ Int J Mol Sci, 2024, 25(1)627] PubMed: 38203798
Gasdermin D licenses MHCII induction to maintain food tolerance in small intestine [ Cell, 2023, 186(14):3033-3048.e20] PubMed: 37327784
Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination [ Theranostics, 2023, 10.7150/thno.81650] PubMed: 37908730
AHR-mediated DNA damage contributes to BaP-induced cardiac malformations in zebrafish [ Sci Total Environ, 2023, 906:167636] PubMed: 37806592
AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME-conferred pyroptosis in non-small cell lung cancer [ J Cell Mol Med, 2023, 27(16):2412-2423] PubMed: 37438979
AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME-conferred pyroptosis in non-small cell lung cancer [ J Cell Mol Med, 2023, 27(16):2412-2423] PubMed: 37438979
High‑throughput screening identification of a small‑molecule compound that induces ferroptosis and attenuates the invasion and migration of hepatocellular carcinoma cells by targeting the STAT3/GPX4 axis [ Int J Oncol, 2023, 62(3)42] PubMed: 36825585
Recapitulating early human development with 8C-like cells [ Cell Rep, 2022, 39(12):110994] PubMed: 35732112
ZBTB7A promotes virus-host homeostasis during human coronavirus 229E infection [ Cell Rep, 2022, 41(4):111540] PubMed: 36243002

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.